<DOC>
	<DOCNO>NCT00193414</DOCNO>
	<brief_summary>This study design study role active well-tolerated non-platinum agent , gemcitabine , combination regimen pemetrexed first-line treatment advance NSCLC . This study serve define role next generation agent new combination regimen treatment advance NSCLC . This combination regimen may ultimately important expand treatment option patient improve survival , quality life , symptom control compare platinum-based combination regimens - acceptable toxicity .</brief_summary>
	<brief_title>Pemetrexed Gemcitabine Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Pemetrexed + Gemcitabine</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>To include study , must meet following criterion : Histologically confirm nonsmall cell bronchogenic carcinoma Newly diagnose recurrent unresectable stage III stage IV disease No mixed tumor small cell anaplastic element Measurable disease Must receive prior antineoplastic chemotherapy lung cancer Age &gt; 18 year Able perform activity daily live little assistance Adequate bone marrow , liver kidney Understand nature study give write informed consent . You participate study follow apply : Female patient pregnant lactate History serious cardiovascular disease within previous six month Serious active infection time treatment Other serious underlie medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>